A new study provides the first strong statistical and laboratory evidence that a large proportion of cerebral palsy cases are caused by mutations in a single gene. These findings will directly inform clinical care by improving physicians’ ability to identify the cause of an individual’s cerebral palsy, which will provide closure for families, guide preventative health care and can even alter the course of treatment.
Category Archives: AZBio News
Puritize®, a new UV-C Home Sanitizing System, Announces Results of SARS-CoV-2 Scientific Testing
Puritize®, the first scientifically proven, patented product available for home use for killing more than 99.9% of germs, bacteria and viruses, including SARS-CoV-2, on personal items, is now available to consumersContinue reading
ClōSYS CEO Jim Ratcliff Wins CEO Today USA Award
SCOTTSDALE, AZ (September 24, 2020) –– James (Jim) Ratcliff, Ph.D., Chairman and CEO of Rowpar Pharmaceuticals Inc., the makers of the ClōSYS brand of oral care products, has been named a 2020 CEO Today USA Award winner.Continue reading
Now Is Not The Time To Lift Mask Requirements
- Rolling back mask and distancing mandates now will reverse gains in slowing the spread
- AZBio PSA Reminds Arizonans to Make Good Choices and Mask Up
- Banner Health opposes lifting mask mandates
Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate
First participants dosed in Phase 3 trial (ENSEMBLE) evaluating safety and efficacy of Janssen’s COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.SContinue reading
Systems Oncology, an AI-based cancer therapy discovery and development company, is honored with a 2020 AZBio Fast Lane Award
Systems Oncology is using AI to Innovate Drug Discovery & DevelopmentContinue reading
Aqualung Therapeutics Corp. Awarded $300 Thousand From National Institute of Health (NIH) to Develop a Novel Therapeutic for Pregnant Women at Risk for Preterm Births
TUCSON, AZ / ACCESSWIRE / September 22, 2020 / Aqualung Therapeutics, an early-stage biotech company developing an immune-focused, anti-inflammatory therapeutic platform for unchecked inflammation in patients with serious acute and chronic diseases, has been awarded a one year NIH FAST-TRACK AWARD (1R41 HD101202-01A1) to support development of a humanized antibody therapy for pregnant women with intrauterine infection at risk for preterm birth.Continue reading
NIH expands clinical trials to test convalescent plasma against COVID-19
Rigorous studies to build on earlier efforts to test the experimental treatmentContinue reading
C-Path Launches Consortium to Accelerate Medical Product Development in Sickle Cell Disease
September is National Sickle Cell Awareness Month
TUCSON, Ariz., Sept. 17, 2020 — The Critical Path Institute (C-Path) today announced the launch of the Critical Path for Sickle Cell Disease (CP-SCD) Consortium to support collaboration and regulatory endorsement of new medical product development tools for sickle cell disease. These tools will help to optimize and de-risk clinical trials to increase efficiency in developing and delivering safe, effective treatments for people living with sickle cell disease.Continue reading
Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting
– Primary endpoint of viral load change from baseline at day 11 was met for one of three doses; consistent effects of viral reduction seen at earlier time points
– Rate of hospitalizations and ER visits was 1.7 percent (5/302) for LY-CoV555 versus 6 percent (9/150) for placebo–a 72 percent risk reduction in this limited population
– LY-CoV555 was well-tolerated across all doses with no drug-related serious adverse events reported
INDIANAPOLIS, Sept. 16, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced proof of concept data from an interim analysis of the BLAZE-1 clinical trial, showing a reduced rate of hospitalization for patients treated with LY-CoV555. The randomized, double-blind, placebo-controlled Phase 2 study evaluated LY-CoV555, a SARS-CoV-2 neutralizing antibody, for the treatment of symptomatic COVID-19 in the outpatient setting. The trial enrolled mild-to-moderate recently diagnosed COVID-19 patients across four groups (placebo, 700 mg, 2800 mg, and 7000 mg).Continue reading